Tesamorelin

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) consisting of all 44 amino acids of native GHRH with a trans-3-hexenoic acid modification. Marketed under the brand name Egrifta®, tesamorelin is the only GHRH analog currently FDA-approved for therapeutic use—specifically for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. Unlike direct growth hormone administration, tesamorelin stimulates the pituitary gland to produce and release endogenous GH, maintaining physiological feedback mechanisms. Beyond its approved indication, tesamorelin is being actively researched for applications in non-alcoholic fatty liver disease (NAFLD), cognitive function in aging, and metabolic health optimization.

Tesamorelin is a synthetic 44-amino-acid peptide analog of Growth Hormone-Releasing Hormone (GHRH)^[1]. It stimulates endogenous growth hormone release and raises IGF-1 levels, leading to enhanced lipolysis and metabolic benefits^[2]. Tesamorelin is FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy and is studied for metabolic disorders and aging research^[3][4].

Storage Instructions

Proper storage preserves peptide quality and efficacy.

• Lyophilized: Store at 2–8 °C (35.6–46.4 °F); newer formulations (Egrifta SV) stable at 20–25 °C (68–77 °F) before reconstitution^[1].
• Reconstituted (with bacteriostatic water): Refrigerate at 2–8 °C (35.6–46.4 °F); use within 7 days^[1].
• Reconstituted (with sterile water): Use immediately; discard any unused portion^[1].
• Do not freeze reconstituted solution; avoid repeated freeze-thaw cycles.

How It Works

esamorelin mimics natural human GHRH by binding to pituitary GHRH receptors, triggering pulsatile growth hormone secretion and consequent IGF-1 elevation^[2]. This cascade promotes lipolysis (fat breakdown), protein synthesis, and favorable metabolic shifts. In HIV-associated lipodystrophy, daily tesamorelin significantly reduces visceral adipose tissue and improves lipid profiles over 6–12 months^[3][4]. Research also explores tesamorelin’s potential to reduce liver fat in NAFLD patients and enhance cognitive function in older adults by restoring age-related GH/IGF-1 declines^[4].

Potential Benefits & Side Effects

Observations from clinical trials and FDA-approved use.

Potential Benefits:

• Significant reduction in visceral adipose tissue (measurable after 3–6 months)^[3].
• Improved lipid profiles and potential liver fat reduction in NAFLD^[4].
• Enhanced cognitive function in older adults (research ongoing)^[4].
• Well-tolerated with maintained benefits during continuous use up to 52 weeks^[3].

Common Side Effects:

• Injection-site reactions: Mild redness, itching, pain, or bruising at injection area^[9].
• Musculoskeletal symptoms: Joint pain (arthralgia), muscle aches, peripheral edema (mild swelling)^[9].
• Carpal tunnel symptoms: Occasional tingling or numbness in extremities (dose-dependent, reversible).
• Metabolic monitoring: IGF-1 elevation requires monitoring; small increases in HbA1c observed in some patients^[9].

Lifestyle Factors

Complementary strategies for optimal outcomes.

• Combine with a balanced, protein-forward diet to support GH/IGF-1 anabolic effects.
• Integrate resistance training and aerobic activity to maximize fat loss and metabolic benefits.
• Prioritize 7–9 hours of quality sleep to optimize natural GH pulsatility.
• Manage stress through mindfulness or relaxation techniques to support adherence and recovery.

Reference

• Tesamorelin – LiverTox: Clinical and Research Information on Drug-Induced Liver InjuryNational Institutes of Health, NIDDK (2018)
• Tesamorelin (Subcutaneous route) – Drug InformationMayo Clinic / IBM Merative (2025)
• Effects of tesamorelin (TH9507), a growth hormone–releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trialsJ. Clin. Endocrinol. Metab. (2010)
• Safety and metabolic effects of tesamorelin in patients with type 2 diabetes: A randomized, placebo-controlled trialPLoS ONE (2017)
• Tesamorelin can improve cognitive function (Research Highlight)Nature Reviews Endocrinology (2012)
• Tesamorelin Injection – MedlinePlus Drug InformationMedlinePlus (U.S. National Library of Medicine) (2025)
• Tesamorelin: Uses, Dosage, Side Effects, WarningsDrugs.com (AHFS Monograph & Patient Info) (2025)
• Tesamorelin – LiverTox (Safety Profile)NIH NIDDK LiverTox Database (2018)
• Administration of Parenteral Medications – Nursing Skills (Open RN Textbook)Open RN, Chippewa Valley Technical College (2023)